Baudax Bio, Inc.

NASDAQ (USD): Baudax Bio, Inc. (BXRX)

Last Price


Today's Change

+0.002 (10.00%)

Day's Change

0.02 - 0.022

Trading Volume



Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare


CEO:  Dr. Geraldine A. Henwood Ph.D. Dr. Geraldine A. Henwood Ph.D.

Full Time Employees:  9 9

IPO Date:  2019-11-14 2019-11-14

CIK:  0001780097 0001780097

ISIN:  US07160F4046 US07160F4046

CUSIP:  07160F206 07160F206

Beta:  1.58 1.58

Last Dividend:  0.00 0.00

Dcf Diff:  28.74 28.74

Dcf:  29.92 29.92


Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.


490 Lapp Road,
Malvern, PA 19355, US

484 395 2440

Be the first to like this. Showing 0 of 0 comments

Post a Comment